title: Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers.
abstract: Adiponectin, a hormone secreted by adipocytes, has insulin-sensitizing, antidiabetic, antiinflammatory, and antiangiogenic properties. The authors conducted a nested case-control study in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort, a cohort of male Finnish smokers aged 50-69 years at baseline, to test whether prediagnostic adiponectin concentrations are associated with pancreatic cancer. Between January 1985 and October 2004, 311 incident exocrine pancreatic cancer cases were diagnosed among cohort participants with serum samples. Controls (n = 510) were alive and free of cancer at the time the case was diagnosed and were matched to the cases by age and date of blood drawing. The authors used conditional logistic regression adjusted for smoking, blood pressure, and C-peptide level to calculate odds ratios and 95% confidence intervals for pancreatic cancer. Higher adiponectin concentrations were inversely associated with pancreatic cancer (for highest quintile (> 9.8 microg/mL) vs. lowest (< or =4.6 microg/mL), odds ratio = 0.65, 95% confidence interval: 0.39, 1.07; P-trend = 0.04). The inverse association was significant among cases diagnosed 5 or more years after blood collection (n = 238) (for highest quintile vs. lowest, odds ratio = 0.55, 95% confidence interval: 0.31, 0.98; P-trend = 0.03). These results support the hypothesis that higher adiponectin concentrations may be inversely associated with the development of pancreatic cancer.
authors.affiliation: Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics,National Cancer Institute, 6120 Executive Blvd., Suite 320, Bethesda, MD 20852, USA. rs221z@nih.gov
authors.forename: Rachael Z
authors.initials: RZ
authors.lastname: Stolzenberg-Solomon
authors.forename: Stephanie
authors.initials: S
authors.lastname: Weinstein
authors.forename: Michael
authors.initials: M
authors.lastname: Pollak
authors.forename: Yuzhen
authors.initials: Y
authors.lastname: Tao
authors.forename: Philip R
authors.initials: PR
authors.lastname: Taylor
authors.forename: Jarmo
authors.initials: J
authors.lastname: Virtamo
authors.forename: Demetrius
authors.initials: D
authors.lastname: Albanes
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D016022:Case-Control Studies; D004311:Double-Blind Method; D005387:Finland / Q000453:epidemiology; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology; D012042:Registries; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects* / Q000453:epidemiology
chemical_list: D052242:Adiponectin
references.citation: Am J Epidemiol. 2001 Apr 1;153(7):680-7
references.pmid: 11282796
references.citation: Int J Obes Relat Metab Disord. 2001 Aug;25(8):1225-32
references.pmid: 11477508
references.citation: Diabetes Care. 2007 Mar;30(3):561-7
references.pmid: 17327321
references.citation: Int J Cancer. 2007 May 1;120(9):1993-8
references.pmid: 17266034
references.citation: J Clin Endocrinol Metab. 2007 Apr;92(4):1510-6
references.pmid: 17213279
references.citation: Exp Gerontol. 2007 Jun;42(6):463-71
references.pmid: 17507194
references.citation: Pancreas. 2007 Jul;35(1):16-21
references.pmid: 17575540
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2101-9
references.pmid: 17905943
references.citation: Am J Clin Nutr. 2007 Sep;86(3):s858-66
references.pmid: 18265479
references.citation: Am J Epidemiol. 2008 Mar 1;167(5):586-97
references.pmid: 18270373
references.citation: Am J Clin Nutr. 2008 Apr;87(4):801-9
references.pmid: 18400700
references.citation: JAMA. 2001 Aug 22-29;286(8):921-9
references.pmid: 11509056
references.citation: Am J Epidemiol. 2002 May 1;155(9):783-92
references.pmid: 11978580
references.citation: Diabetes. 2002 Jun;51(6):1884-8
references.pmid: 12031977
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):403-12
references.pmid: 10794485
references.citation: JAMA. 2000 May 17;283(19):2552-8
references.pmid: 10815119
references.citation: Cancer Causes Control. 2000 Dec;11(10):915-23
references.pmid: 11142526
references.citation: Gastroenterology. 2001 Apr;120(5):1263-70
references.pmid: 11266389
references.citation: Cancer Causes Control. 2002 Jun;13(5):417-26
references.pmid: 12146846
references.citation: Acta Oncol. 2002;41(4):381-8
references.pmid: 12234031
references.citation: Lancet. 2003 Jan 18;361(9353):226-8
references.pmid: 12547549
references.citation: Diabetologia. 2003 Apr;46(4):459-69
references.pmid: 12687327
references.citation: Heart. 2003 Jun;89(6):663
references.pmid: 12748229
references.citation: Br J Cancer. 2003 Aug 4;89(3):519-23
references.pmid: 12888824
references.citation: Histol Histopathol. 2004 Jul;19(3):999-1011
references.pmid: 15168361
references.citation: Mol Cancer. 2003 Jan 6;2:4
references.pmid: 12556242
references.citation: Curr Pharm Des. 2004;10(23):2827-37
references.pmid: 15379671
references.citation: Am J Epidemiol. 1986 Jul;124(1):17-27
references.pmid: 3521261
references.citation: Am J Epidemiol. 1988 Sep;128(3):655-66
references.pmid: 2458036
references.citation: Ann Epidemiol. 1994 Jan;4(1):1-10
references.pmid: 8205268
references.citation: Diabete Metab. 1993 Sep-Oct;19(5):458-62
references.pmid: 8056126
references.citation: Circulation. 1963 Jul;28:52-7
references.pmid: 14032101
references.citation: Cancer Causes Control. 2004 Nov;15(9):873-81
references.pmid: 15577289
references.citation: JAMA. 2005 Jan 12;293(2):194-202
references.pmid: 15644546
references.citation: Atherosclerosis. 2005 Apr;179(2):421-2
references.pmid: 15777563
references.citation: Hypertension. 2005 Jun;45(6):1094-100
references.pmid: 15897361
references.citation: Br J Cancer. 2005 Jun 6;92(11):2076-83
references.pmid: 15886696
references.citation: Pancreatology. 2005;5(6):514-29
references.pmid: 16110250
references.citation: J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27
references.pmid: 16204691
references.citation: J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94
references.pmid: 16288122
references.citation: Br J Cancer. 2005 Nov 28;93(11):1310-5
references.pmid: 16288300
references.citation: Lipids Health Dis. 2005;4:27
references.pmid: 16262911
references.citation: JAMA. 2005 Dec 14;294(22):2872-8
references.pmid: 16352795
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):879-85
references.pmid: 16702364
references.citation: Cell Cycle. 2006 Jun;5(11):1160-3
references.pmid: 16721061
references.citation: J Clin Invest. 2006 Jul;116(7):1784-92
references.pmid: 16823476
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1331-5
references.pmid: 16835332
references.citation: Expert Opin Investig Drugs. 2006 Aug;15(8):917-31
references.pmid: 16859394
references.citation: Clin Chim Acta. 2006 Aug;370(1-2):63-71
references.pmid: 16530178
references.citation: Cancer Res. 2006 Oct 15;66(20):10213-9
references.pmid: 17047087
references.citation: J Clin Endocrinol Metab. 2006 Dec;91(12):5002-7
references.pmid: 17003098
references.citation: J Clin Endocrinol Metab. 2007 Jan;92(1):255-63
references.pmid: 17062769
references.citation: Cancer Causes Control. 2007 Mar;18(2):165-75
references.pmid: 17219012